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Abstract

This research explores how the CDC Hepatitis Epidemiology Investigation Team at the
Philadelphia Department of Public Health (PDPH) constructs Hepatitis C (HCV) in the public
and medical discourse through their monitoring and education activities. Data in the form of field
notes and ethnographic observation was collected during 16 months of participant observations
at the Philadelphia Department of Public Health. This research provides evidence that the team’s
actions give voice to a silent epidemic by being responsible for the construction of the
conversations happening around HCV in Philadelphia. Their actions in the domains of risk
factors, support systems, public health and prevention, stigmatized behaviors and safe practices,
bodily proof and silent epidemics, health insurance, and medical hierarchy will ultimately
determine the future climate of hepatitis in Philadelphia. This research can serve as insight into
the functioning of public health teams and how more positive and proactive conversations
surrounding diseases can be instigated.
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Introduction
I would like to preface this piece by putting forth that it is not an investigation into how a
disease is conceptualized by the population burdened by it as we so often do within medical
anthropology. There were no interviews with patients on their perceptions of their illnesses. It is
also not an evaluation of a public health intervention with an anthropological critique to improve
effectiveness. This paper is an investigation into how one team operationalizes a disease in their
research. The research serves as an ethnographic snapshot into how a group of health scientists
perform their work and what that work means to the greater community.
Hepatitis has often been referred to as a “silent epidemic (Chen, 2002).” This label
highlights the fact that the viruses that cause hepatitis A, B, C, D and E are not part of the public
discourse of disease. The risk factors, methods of prevention, methods of transmission, and
treatment are not common knowledge contributing to its status as a “silent epidemic.” As seen
with many other diseases, without conversation, action is not taken (Yamey, 2002). The CDC
decided to spark the conversation about hepatitis in the United States when in 2013 it granted 5
cities the ability to expand their hepatitis surveillance.
While the CDC’s expectations were data collection in order to further understand the true
impact of hepatitis, there have been many other impacts in Philadelphia with the implementation
of this grant. This research investigation did not originally set out to identify how researchers
create a new space for the discussion and public discourse of HCV, but rather to understand
more broadly the burden of HCV in Philadelphia. Through observation a trend emerged that
influenced the way in which findings are presented in this paper. In the hepatitis team’s efforts to
gather data, I began to notice domains in which they a created a space for discussion. Whether
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that discussion is positive or negative will be played out in the coming years and presents itself
as the future trajectory of this research.
In order to better understand the point of this research and the impact of the team on this
ambiguous “culture of hepatitis” in the city, I call upon the example of HIV/AIDS. When
HIV/AIDS entered the public discourse it was met with social stigmas surrounding homosexuals
and later race, tainting the space it occupied as negative (Harris, 2009). This negative
conversation impacted everything from support systems to insurances statuses. We can contrast
this disease space with that of breast cancer which has a far more positive public discourse
surrounding it. How the hepatitis team operates, what they emphasize and highlight, and who
they interact with all create the space in which hepatitis can be constructed, understood, and
lived in Philadelphia. The domains selected for observation in this paper are risk factors, systems
of support, public health and prevention, stigmatized behaviors and safe practices, bodily proof
and silent epidemics, health insurance, and medical hierarchy. A deeper delve into the team’s
actions in each of these areas will provide a further understanding of the construction of the
aforementioned “space.”
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Background: Significance of Hepatitis C as a Global “Silent Epidemic”
HCV as a Global Burden
Viral hepatitis is a growing global concern as prevalence and mortality rates continue
to rise and many worry it will be a pandemic that will possibly overtake HIV (Morris, 2013).
With the introduction of the new drug regimens and the patterned stigmatization attached to
Hepatitis C (HCV) transmission, which mirrors that of HIV, it is possible that we may be
able to do for hepatitis what we have done for HIV. In 2010, there were 1.4 million deaths
from H epatitis B (HBV) and C, a number just shy of the number killed by HIV(Morris,
2013). Hepatitis, in all its viral forms combined, is the 8th leading cause of death worldwide.
In Asia, the combined infection rates for HBV and HCV are greater than 20%, only further
substantiating the claim that HCV is a significant health burden (Morris, 2013).

HCV and Global Public Health Programming
HCV has been ignored by many of the global leaders in public health. The United Nations
Millennium Development Goals’ focus has left HCV to be considered mainly as a coinfection with HIV, not as its own illness. This lack of visibility leads to a lack of funding.
For example, Mongolia and Vietnam have HBV and HCV rates as high as 20% and HIV
infection rates less than 0.5%, yet they have dedicated staff and programs for HIV, but not
hepatitis (Morris, 2013). The World Health Organization (WHO) regional office for the
Americas was even on the verge of dropping hepatitis from their 2014-2019 strategy due to
lack of funding. However, there are those offering solutions. The Global Commission on
Drug Policy has called to divert resources from the war on drugs and other drug policies to
fuel HCV treatment (Morris, 2013). This is a fitting proposal considering a common means of
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transmission of HCV is through injection drug use (IDU). Despite clear knowledge of this
fact, on the local level within the State of Pennsylvania, needle exchange programs are
considered an illegal operation due to “encouraging drug use.” If less time and money was put
into fighting drug use and rather approaching it as a public health concern, HCV transmission
rates could be greatly reduced.

Domestic HCV Situation
Within the United States it is difficult to estimate the number of people with chronic HCV
infection. Not everyone who would qualify for therapy has been tested and identified, referred
for appropriate care, and offered or given the best therapy available (Holmberg, et al, 2013).
There are an estimated 3.2 million people in the US with chronic HCV infections, of that 1.6
million (50%) had HCV detected through testing and of those people, 1.0-1.2 million (3238%) were referred to care. Of those who have been referred to care, only 220,000-360,000
(7-11%) were treated and of those treated 170,000-200,000 (5-6%) were successful in their
treatment (Holmberg, et al, 2013). In order to address increased testing the Centers for
Disease Control and Prevention (CDC) recommends a one-time test for everyone born
between 1945 and 1965 to help identify people who would not be normally targeted (an age
cohort). The CDC has also been releasing large grants to improve the monitoring and
surveillance of hepatitis in order to better assess the status in the United States. One of these
grants is the focus of this paper. The most common risk factors for the contraction of HCV
include IDU, tattooing, and men who have sex with men (MSM). Many people are unaware
that they need to be tested because they have none of these risk factors, however, before 1991,
blood transfusions were not screened for HCV and many people obtained the infection in this
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way (Holmberg, et al, 2013). Based on the previously stated data, it is right to deduce that
within the United States, there is a silent epidemic of viral hepatitis.

Hepatitis Interventions
The most positive developments in the field of hepatitis are in the work of immunization
campaigns for HBV. Unfortunately, no vaccine exists for HCV and prototypes are, at best, at
the preclinical phases of development (Morris, 2013). For this reason, the most effective steps
that can be taken towards reducing HCV rates are in the area of treatment; those who are cured
can no longer transmit the virus. Protease inhibitors, a class of drugs which prevent viral
replication, such as tenofovir, boceprevir, and taleprevir have already transformed chronic
hepatitis management and in the next 2-5 years, 90% of HCV infections will be curable with a
once-daily, 12 week, low toxicity, oral regimen (Morris, 2013). Other countries have already
proven the successfulness of integrated testing campaigns – something not seen in
Philadelphia. The United Kingdom predicts that with their aggressive testing and treatment
programs they can eradicate HCV by December 2027 (Morris, 2013). Yet no initiatives on
such a massive and integrated scale have been proposed in the United States, on the national,
state or city level.
HCV is coming upon a revolution: New drugs are about to enter the market and change the
way in which patients and doctors think about treatment. A major barrier facing the
implementation of these new drugs is the enormous cost. A course of treatment will cost
between $60,000 and $100,000 (Holmberg, et al, 2013). Under the Affordable Care Act
(ACA), states had the option to expand their Medicare and Medicaid packages; however, some
states chose to not opt in. Pennsylvania is one of those states. There has yet to be research on
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what this means to the future of HCV treatment, especially considering the demographics of
who carries the largest burden of the disease, which still requires further exploration in across
the United States. In order to properly address treatment and prevention gaps in hepatitis, a
greater emphasis needs to be placed on understanding the medical system and public discourse
of hepatitis as a whole.
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Methodology
In order to answer the queries posed in the introduction, the research method selected was the
use of ethnography. Qualitative data was collected through participant observation that lasted the
duration of 16 months, averaging 10 hours a week in the field. Ethnographic data provides the
opportunity for careful the daily, inner-workings of the Hepatitis Team. Quantitative data on
hepatitis statistics and team productivity or short-term field work would not be able to
comprehend the nuances of team interactions. This form of data collection allowed a thorough
development of relationships with the subjects of interest to see how operations go in a natural
environment. Data collected through this means was done via handwritten field notes that were
later typed for analysis. The field notes were then analyzed using nVivo software so as to
identify themes and trends.
I gained entry to the PDPH and the hepatitis team through a previous relationship as an
assistant to the team and the Division of Disease Control. This relationship gained me access to
both the team and the other groups that they interact with, mainly HepCAP and Prevention Point.
Interviews were excluded from the methods per the subjects’ request so all data was dependent
on participant observation. The exclusion of one-on-one interview did not affect the research as
much as anticipated due to the nature of the research observing how the team interacts with their
work, not necessarily looking too deeply at what they have to say about their jobs. Most
information that would have come from interviews came out natural through informal
conversations and through my attendance at weekly meetings. Necessary context information
was gained through the long duration spent in the field. Ethnography ultimately allowed for the
exploration of this team in a more flexible way as opposed to a pre-set, rigid methodology set on
testing a specific hypothesis (Hahn, 1999).
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Results
The Field Site
The field site was the Philadelphia Department of Public Health, Health Center #1 at 500
S. Broad Street along Avenue of the Arts in Downtown Philadelphia. The building is an old
theater built of green bricks transformed into a sea of cubicles. The building smells of the lab on
the upper floor. The office is fairly noisy due to the acoustics of the sourcing ceiling that once
served to project performances. While the maze of cubicles seems hectic at first, it is an
organized chaos of teams and departments. My observations began the fall of 2013 and ran
through March of 2015 with time off during the summer months for a total of 16 months,
averaging 10 hours a week. Observation time was split between assisting in data entry and
attending to my personal research.
The spaces within the site that provided observations were the Hepatitis Investigators’
(Hepi’s) cubicle section, the Division of Disease Control central desk unit, Board Room 1 where
weekly meetings occurred, Board Room 3 where meetings with the entire DDC group took
place, the building auditorium where HepCAP support group meetings took place every other
Wednesday night, and at Prevention Point in North Philadelphia.
The PDPH is first and foremost a place of science. Scientific method and means of
evaluation and quantification are in everything that is done. It is therefore important to
understand that in this field site, hepatitis C is understood as a biological conditional caused by a
viral infection of the liver. There are no other acceptable explanations to this team as their work
is based off a belief in this as an absolute fact. With other medical anthropology field sites, an
investigation into how the population perceives their bodies and the causes of their disease is
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necessary, however, this site is clear with a Western biomedical model of understanding
(Scheper-Hughes and Lock, 2009).

The Grant
In May 2013, the Philadelphia Department of Public Health announced to greater
Philadelphia that they would be doing increased surveillance of hepatitis (Figure 1). This
announcement followed the receiving of a large CDC grant to the PDPH to collect further
metrics on the epidemiology of hepatitis. The PDPH had to make adjustments within its Division
of Disease Control to accommodate the additional staff, but the prestige and size of the grant was
enough motivation to expand as necessary. The investigation team even received a brand new
cubicle room complete with a door and new chairs. When I joined the field site, the grant’s
activities had been underway for only four months. Upon completion of my research, they were
only halfway through the grant duration of five years. Data and surveillance will still be ongoing
until 2018.
The grant deserves to be mentioned in its own section because of the significance that
grants of this kind have in influencing the disease conversation. This grant could have easily
been about any other disease and hepatitis would not have had its time to prove its importance in
the public discourse. Timing and influence of new pharmaceuticals about to come to market as
likely put some pressure for increased surveillance (Pawlotsky, 2014). The grant’s focus was
surveillance, but it also included an education component that required the team to disseminate
information to both patients and providers. The structuring of the grant to include a section on
education is also important to the power inferred to the team to influence the conversation
around HCV.
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The Team
There are 7 people at the PDPH on the hepatitis team. The team is made up of a director
(PhD), epidemiologist (MA), education outreach (MA), web and materials designer (BA), and 3
hepatitis investigators (BA’s). The blending of degrees and expertise creates a well balanced
team that is not too heavy in any one particular perspective or field of study. Public health often
draws from various degrees and levels of professionals to achieve its results valuing the different
experiences each individual has to offer.
Kendra, in her role as director, overlooks all activities while troubleshooting problems.
Danica is the epidemiologist whose job it is to assemble the data into reports and statistics to
monitor program advancement and report back to the CDC. Erin, the education outreach
position, works directly with the web and materials designer and has limited interaction with the
rest of the team. The web and materials designer, Evan, is the only male on the team and the
newest addition. His job is to produce the educational materials and design the new website.
Finally, there are the 3 female hepatitis investigators or “Hepis (Hep-ees)” who performed the
bulk of the work in data collection and have direct patient and doctor interaction. The Hepis and
their work are the main focus of my research since they have the most influence over how the
program is played out and how relationships with providers and patients are developed.
The team works in two separate parts of the field site with Hepis seated in one cubicle
section and the rest in a different office. This separation established a hierarchy between the two
parts of the team divided by degrees and age. The team meets every Wednesday morning for an
hour to discuss Hepi investigations and trouble-shoot problems. Every other Friday they get
together for a two hour meeting that involves a time to catch up on the most recent literature in
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the subject area, discuss upcoming presentations at universities or health centers, and strategize
long-term program goals.
The Hepis are fresh college graduates working their way towards grad school or enrolled
concurrently. Their responsibility is to make phone calls to patients and doctors to ask a schedule
of questions that determine the point of infection as well as ask general demographic
information. This sometimes involves doing home or office visits to audit records or track down
patients. They also flag cases that are unusual or should be under close monitoring. These cases
include pregnant mothers, acute HBV cases, and cases of re-infection. They report directly to the
epidemiologist and utilize the director as a means to troubleshoot noncompliant doctors or
difficult patients .At the start of the program, each Hepi had a different take on the research at
hand. While some took the intimate phone call interviews with a grain of salt, others were deeply
affected by the conversations when patients or physicians reacted negatively. By the end of the
first year, they had all become hardened veterans. They also began to create their own ideas for
education and survey questions including the translation of patient letters and asking patients
about their health insurance status.
Looking at the motives for each person’s involvement on the team lends insight into the
way in which public health operates. For Danica and Kendra, both specialized in infectious
disease, working on a hepatitis project was something they always wanted to do. The education
outreach coordinator had personal experience with gay friends who had been affected by HCV
and took the job coming from previous work with the HepCAP support group. The materials
designer had transferable skills and took the job because it was what was available. Motives for
Hepis being a part of the team were split. Two Hepis had no hesitation in stating that they were a
part of the team because they needed it on their resumes for graduate school. The other, a Penn
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graduate of 2013 and Health and Societies major said she was curious and having never given
much thought to hepatitis before. Given her education and background, her lack of knowledge on
hepatitis serves as further evidence for the overall absence of conversation surrounding the
disease. Despite individual motives, there universally appeared to be a strong desire to create an
impact. This was evidenced to me by the team’s enthusiastic involvement in their testing of
people at the local needle exchange program (NEP), Prevention Point. They all went through
phlebotomy training to learn how to draw blood and take turns every Friday testing patients and
conducting interviews in person.

The Work
The work of the team can be divided into 3 main categories: Patient and provider
investigations, patient and public education, and data analysis. Each part plays an important role
in the overall completion of the program with various members of the team working on different
parts.
Investigations are the domain of the Hepis. This is the point of contact with providers and
patients and serves as primary data collection. Newly reported cases to the PDPH are sorted by
Danica and then “pushed” on the Communicable Disease Management System to the Hepis
based on the zip code in which the patient resides. This means the file for the patient is
electronically sent to a personalized workflow for the Hepi to access. Each Hepi has their own
set of zip codes they are responsible for with an even distribution of low prevalence and high
prevalence zones. Hepis then send a letter to the patient and their provider warning them of an
upcoming interview. This gives the recipients the opportunity to call the Hepis first or wait for a
Hepi to reach out to them in the next few days. About half of the time the patient will call first
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having been alarmed by the letter they received in the mail. Once the patient calls, the Hepi will
ask them to participate in important data collection for the CDC to help understand how people
contract hepatitis in Philadelphia. Most patients comply with an interview while some do choose
to opt out. The standard survey includes demographics, medical history, risk factor questions,
and questions about treatment and interactions with their physician averaging about 10-15
minutes. The provider schedule of interview questions is the same as the patient’s, however,
provider calls prove to be the largest obstacle faced by the Hepi team. There is more on why this
is a challenge for the Hepis that will be discussed in detail in the Medical Hierarchy subsect of
the Discussion section.
The Hepis incorporate education opportunities into the interviews. At the end of
interviews, Hepis ask if the patient or doctor’s office would like to receive additional materials
on hepatitis. This is just one of the elements of the education and outreach component of the
grant. There is also education outreach through partnership with the local HepCAP support group
where the team makes frequent presentations and disseminates educational materials. For the
work done at the local needle exchange program (NEP) Prevention Point, there are materials
specifically designed for this transient population. These materials include discreet appointment
cards and education cards that fit into a wallet. The need for wallet-sized education materials that
were focused on compliance came from observation of the population at the NEP and their
specific needs. The education team is also responsible for the creation of the website to educate
the Philadelphia public about hepatitis. This project is nearing completion and has not gone live
yet. The interpretation of education intervention as stipulated by the grant is lose and this
component tends to be created as needs are seen in the community.
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The final component of the work done by the team is compiling the data for analysis by
the epidemiologist. Danica’s entire job is focused around running reports and creating statistics
for the CDC. While the least exciting role to execute, Danica’s data analysis is the fruit of all the
team’s labors. Due to competition with the New York City Department of Health, I was unable
to use any of the data gathered by the program for this paper. The team has not officially
published any of the findings and considers themselves in direct competition with NYC for the
best hepatitis surveillance in the country. They did not want to risk their data being leaked to the
NYC department.
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Discussion: Constructing the Conversations
In observing the daily activities of the hepatitis team, their actions and the impacts of
those actions began to emerge as a theme. The results of their interventions extend beyond the
gathering of data and are constructing the atmosphere in Philadelphia surrounding the diagnosis,
treatment, and prevention of HCV. The realms of influence that the team is instigating
conversation and change in are discussed throughout the rest of this section. For an abbreviated
illustration of the information, please refer to Table 1.

Around Risk Factors
A frequently faced challenge of the team involved the identification of infection through
risk factors. This challenge originated not because the means of identification of infection are
difficult, but rather because questions about risk factors are laden with social stigma. When a
question makes the patient uncomfortable, despite anonymity, they are less likely to respond.
The hepatitis team frequently faces apprehension from patients with the questions involving such
topics as sexual history, drug use, and other social activities such as tattooing. Lack of response
on these questions leaves gaps of knowledge in understanding the hepatitis landscape in
Philadelphia. In order to prevent infections, the team must know where they originate from.
At a Wednesday morning meeting in early fall of 2013, only 4 months after starting the
program, the issue of data collection on risk factors from unwilling participants was brought up.
Two solutions were proposed: 1) Make the questions less direct by asking about other factors in
the person’s life that would indicate such things as sexual preference or use of drugs or 2) leave
the questions out of the patient schedule and put pressure on the doctor to collect that
information. Both solutions were problematic. The first posed the dangers of inaccurate answers
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and a perpetuation of stereotypes that would not be in the vein of good research. The second is
problematic in that it depends on physician participation which had been generally difficult up to
that point. After much back and forth, the team decided the best option would be neither. They
opted to reorder the questions so as to disperse the more shocking inquiries with those that are
more mundane, such as date of last doctor visit. They also chose to introduce most conversations
about Hepatitis C through the “baby boomer angle (“Illness: From Causes to Meaning").” This is
the same angle seen in commercials for Hepatitis C. Proposing first the idea that you could have
hepatitis merely because of your age shifts the blame from the patient making them feel less
under “investigation.”
The issue of risk factor investigations was not only a problem for Hepis on the ground
level, but was problematic for the doctors they worked with. At meetings, in general
conversation, and on site visits, a recurring problem was the issue of doctor involvement in the
diagnosis of HCV. What seems like the doctor’s responsibility had been neglected due to stigma
and avoidance of uncomfortable situations with their patients. The Hepis found that doctors were
not asking risk factor questions because they felt uncomfortable with the questions.
Risk factor awareness is an important way to decrease the number of HCV infections that
occur. Transmissions often occurs when a person in unaware of their status or what behaviors
caused them to become infected in the first place. These conversations need to be happening, but
are often avoided for fear of stigma. The actions taken by the team to make patients more
comfortable in order to gather data is having an impact larger than the grant. The continuing
dialogue with these patients and providers is ultimately creating a space in which the risk factors
are less stigmatized. With less stigmatization patients feel more comfortable coming forward for
diagnosis and treatment. This impact is demonstrated at Prevention Point. While this is a micro
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chasm in Philadelphia, the attitude of the NEP on drug use as a behavioral and health issue as
opposed to criminal offense creates a safe space. Once these patients enter that judgment free
zone they are more likely to be diagnosed and access treatment. The hepatitis team is
contributing to a similar system wide change throughout the Philadelphia medical system.

Around Systems of Support
When dealing with issue of stigma and illness, support systems are often lacking. Those
who find themselves ostracized because of an illness or a behavior are less likely to reach out for
help. This is evidenced by the hepatitis patient interviews where many refuse treatment or
connection to a professional citing embarrassment or frustration with the medical system. The
hepatitis team takes action to create a space in which support can be accessed by those who do
not have other places to turn.
The main actions of the hepatitis team to support those with hepatitis come with their
endorsement of HepCAP, a support group for patients who are HCV or HBV positive. This
activity of providing information extends to Philadelphia clinics where they often drop materials
and talk to physicians and their staff about recognizing risk factors and provide tips about
encouraging compliance with transient patients. The team then takes a step further to connect
these clinics and offices with the support groups and other resources throughout the city that
their patients may need that the doctor is unable to provide. When interacting with patients, the
hepatitis team offers materials and a direct help line that patients can feel free to call with any
questions. The investigators claim that most interviews end up taking10 minutes longer than they
should because the patients end up having many questions that their doctors never addressed
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with them. This one-on-one education is an important element that is unusual for public health to
be able to incorporate since the focus is typically on the population rather than the individual.
These actions ultimately are constructing hepatitis in Philadelphia as something not to be
feared. This is done by creating a space in which the patient feels comfortable and not
discouraged by their diagnosis. They are empowered by information and are aware of the
resources available to them. The team is demonstrating to doctors and communities how support
can be tailored to the individual’s need without much effort. They are most importantly
demonstrating through support that stigma does not need to be part of the Philadelphia hepatitis
conversation.

Around Public Health and Prevention
The ultimate goal of public health is the prevention of disease through close monitoring,
education, and quick and efficient access to treatment resources. Prioritizing prevention of
hepatitis through the gathering of surveillance data is the anticipated outcome of the CDC
program. By understanding the current state of hepatitis infections, the CDC can create
appropriate recommendations for communities to take to halt the spread. This process involves
public health, patient, physician, and community collaboration; something that the hepatitis team
is working on in Philadelphia.
While interviews with already infected patients are a reactive step being taken by the
team, they have many proactive initiatives as well. These actions include their collaboration with
doctors on diagnostic tools, their activity at Prevention Point, and their patient education efforts.
In educating doctors on diagnostic tools, they are more likely to catch cases early before the
patient has the chance to infect another person. They are also able to open conversations up with
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HCV negative patients about watching for behaviors that may expose them. The activities at
Prevention Point stand to redefine drug use as a medical problem as opposed to one of criminal
justice. Through these steps in prevention by educating on behaviors, the team is demonstrating
how social and behavioral changes are part of health and prevention of hepatitis. This
conversation also services to take isolated occurrences of hepatitis in the individual and
contextualize them to the greater community. These actions and their results construct hepatitis
to exist in a health dynamic between individuals, their communities, doctors and the PDPH
which will eventually lead to lower rates of infection.

Around Stigmatized Behaviors and Safe Practices
While stigmatized behaviors involving risk factors has already been touched on, this
section is reserved specifically for the actions being taken at Prevention Point (PP) and through
monitoring of tattoo parlors.
Through their participation in blood draws and interviews at PP, the team is able to spark a
direct conversation with drug users that extends beyond the abilities of a doctor. They are
meeting the users on their own turf in a space that encourages safe practices. Safe practices refers
to the teaching of the use of clean needles and not sharing works, as it relates to cooking and
injecting heroin. Being a part of this clinic and demonstrating to the IDUs that the PDPH does
not see them as an enemy, but rather just as part of the population with health matters, it opens
doors for healthy conversation. The team also actively monitors when a patient is hepatitis
positive from a tattoo they receive in a Philadelphia. Close monitoring of these establishments
ensures community safety and can stop outbreaks early in their tracks while encouraging best
practices of needle replacement (Shaw, 2012).
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The PDPH’s support of NEPs and their monitoring of tattoo parlors demonstrate to
community members that hepatitis is not a personal problem. It portrays hepatitis as something
that the whole community can be a part of to create a healthy environment. When the team
interacts with these stigmatized organizations in a supporting manner, they construct hepatitis in
a safe space characterized by safe practices.

Around Bodily Proof and Silent Epidemics
As previously discussed, the danger of hepatitis exists in its ability to remain in the body
for decades asymptomatically. This results in higher levels of damage than expected as well as a
underestimation by patients of the urgency of the diagnosis. As evidenced by patient interviews,
those who are diagnosed with hepatitis also feel an inclination to deny the problem is serious
because they do not have bodily proof of harm. They find their friends and family do not take the
diagnosis seriously because they do not exhibit jaundice or a sore liver. The hepatitis team takes
direct action to give voice to the silent epidemic and establish irrelevance of bodily proof to
patients.
When talking to patients about hepatitis, the investigation team resorts to a mental health
analysis to make the asymptomatic yet underlying destruction clear. They avoid comparisons
with HIV since there has been confusion in the past with some patients as to their diagnosis.
They utilize a mental health comparison in the following way: As with a mental illness, others
cannot see hepatitis or have a conception of your pain. However, in the case of both hepatitis
and HIV/AIDS, the longer one goes without treatment, the worse they become until the illness is
apparent to everyone. However, by that point, usually more damage is done than can ever be
reversible. This analogy works well for patients in Philadelphia who often cite knowing someone
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in their family with a mental illness and being able to understand the damage that invisible
illness inflicted. This approach is another example of how the team caters their education to the
needs and understanding of the community.
These actions demonstrate to the patients that bodily proof does not need to be a part of
an illness experience. It builds awareness among those with HCV that they should not delay
treatment just because the effects go unfelt for a long time. Hepatitis is therefore constructed in a
space where the infected feel a sense of trust with the medical professionals and their community
in understanding the urgency of their needs.

Around Health Insurance
Health insurance education is not an element of the grant, but given the passage of the
ACA and the necessity of insurance in receiving hepatitis treatment, the team added it to their
agenda. The impacts of discussing insurance with patients may seem like due diligence, but these
conversations are not happening outside of the billing offices and collection calls that patients
receive. Filling this role as educator and connector is a unique role that further empowers the
team and its influence in the City in the realm of hepatitis.
As previously mentioned in the background, Pennsylvania did not opt into the Medicaid
expansion. This decision severely limits the state’s ability to pay for the new HCV treatments
that are coming onto the market. This bodes bad news for those who are on public insurance. The
team directly addresses these issues through patient education, monitoring insurance statuses,
and collaborating with centers of free care. By educating patients in their options for treatment
and how they can access these alternatives, the team is taking steps to educate the public on
health policy. The patient becomes a more active participant in their treatment. Additionally,
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since their healthcare becomes politicalized through these issues of insurance, they also become
more active in the political process. By politically empowering patients through education, the
team is constructing a political space in which hepatitis can exist among an educated voting
population seeking change in health policy.

Around Medical Hierarchy
Power dynamics within medicine were brought forth through the team’s interactions with
both the Department of Health as well as the greater Philadelphia medical community. As
previously mentioned, the investigators interact daily with physicians to conduct interviews.
These interactions brought forth feelings of distrust and frustration.
The predominant way in which a medical hierarchy is observed is through the level of
degree attainment. To work at the Department of Public Health, on a team such as the hepatitis
program, an advanced degree is not necessary. While most people obtain masters and many have
MDs or PhDs, they are not necessary to promote the ideals of public health and work in disease
control and prevention. Everyone is well trained in the field that they specify in. While a doctor
may need to know much more knowledge about various diseases, the hepatitis team only needs
to know hepatitis, so they educate themselves to the fullest extent. This is evidenced by monthly
journal clubs, attendance at hepatitis conferences, and independent research into the topic. For all
intents and purposes, the hepatitis team stands as an authority on the prevention and
epidemiology of hepatitis in Philadelphia, however, this authority is only as good as its
recognition from the medical community, a recognition they struggle to obtain.
Compared to the patients, the doctors are given more power in how they want to respond
to the surveys. Questions are first sent in the mail to the doctors to fill out at their leisure and
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then fax into the Department. If there was no response from the doctors within a reasonable
amount of time, the team calls and reminds them to complete the form, or opt to answer
questions on the phone with them. Most opt to answer the questions on the phone, however,
many others promise to fax back the completed forms ASAP. Visits to doctor’s offices to
perform chart audits are a weekly occurrence for the team due to lack of response.
While doctors have busy schedules, there appears to be a dynamic between the
investigators and the doctors that are uncooperative in surveillance initiatives. There was a
demonstrated lack of respect in the authority of knowledge of the investigation team. This was
evidenced by responses given by the doctors when reminded to complete the forms that included:
“This is unnecessary,” “These are my patients and none of your business,” and “You have no
right to be asking these questions and I have no obligation to respond.” These responses could be
warranted reactions for the sake of protecting the patients’ privacy, or as I would surmise the
reason to be, the doctors’ feeling that their authority and knowledge was being questioned. I
come to this conclusion because after a year and a half of doctor surveys the trend was very
eminent that doctors were not properly screening for hepatitis. Risk factor questions about
lifestyle choices were not being asked during visits. The doctors were defensive that they were
being judged for not doing their jobs properly. What the Department of Health viewed as an
opportunity for collaboration and improvement of health was viewed as a turf war of authority
by physicians. Fortunately, during the year and a half of field work, this dynamic began to shift
as the hepatitis team demonstrated their selves to be committed and not disappearing anytime
soon. Once this trust was established, collaboration on challenges grew exponentially.
Collaboration is beneficial to the PDPH and to the community. In partnership with
physicians, the PDPH legitimizes itself as an authority with doctors and in the community. The
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combined efforts of the two entities also mean higher effort going towards solving the problem
of hepatitis. The community therefore greatly benefits from this partnership. The team is
constructing hepatitis to exist in an environment in which the expertise of everyone involved in
diagnosis, treatment, prevention and monitoring is respected leading to a more efficient system.
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Conclusions
The team gave voice to a silent epidemic by being responsible for constructing the
conversations happening around hepatitis in Philadelphia. Their actions in the domains of risk
factors, support systems, public health and prevention, stigmatized behaviors and safe practices,
bodily proof and silent epidemics, health insurance, and medical hierarchy are contributing to
determining the future climate of hepatitis in Philadelphia.
Research of this kind is not currently being conducted in the City of Philadelphia, or other
urban centers in the United States. This novel investigation contributes to the HCV knowledge
base in an effective and impactful way. It is my hope that this research will contribute to calling
attention to the way in which the public discourse and conversations around HCV is changing in
Philadelphia and how ethnographic research studies can provide insight into the behind the
scenes construction of disease landscapes.

Limitations of the Research
This research does not tell the whole picture of HCV in Philadelphia. It serves as a
snapshot into the work of a team to assess the disease burden amidst pushback, complications,
and unexpected research hurdles. In order for this research to be more complete, interviews with
HCV patients are necessary. Due to IRB restrictions on vulnerable populations and a scope of a
project much larger than possible for this researcher, those questions will be saved for a future
project.
Future Research
Understanding the disease space is important to understanding the patient experience.
While this research did not approach the patient perspective, future studies must. This paper can
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serve as a platform to dive off of into patient experiences. Knowing how the space for diagnosis
and treatment is created can try to place the patient within a greater context. The patient
experience provides necessary critiques and insights into how the clinical and research
conversation created might be flawed or inefficient in its aspirations. One particular realm of
interest would be research into how HCV patients in the City of Philadelphia are transformed
into biological citizens by the discourse that was investigated in this research (Petryna, 2002).
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Figure 1
Health Advisory
Enhanced Surveillance for Viral Hepatitis Beginning in Philadelphia
May 6, 2013
The Philadelphia Department of Public Health (PDPH) has launched an enhanced viral hepatitis
surveillance program. The goal of this program is to better understand the burden of chronic
hepatitis B and chronic hepatitis C and to estimate the level of clinical management for these
diseases in Philadelphia. Surveillance information will be used to inform patient and provider
educational efforts and identify additional areas for public health action.
PDPH investigators will contact providers and patients by telephone or in person to obtain
clinical and risk factor information on positive hepatitis B virus (HBV) and hepatitis C virus
(HCV) test reports received by PDPH. The investigations will be brief – less than 10 minutes for
providers – and will provide valuable insights on Philadelphians living with chronic viral
hepatitis. PDPH thanks you and your office staff for cooperating with these efforts.
We urge you to incorporate the following into your routine practice:
1. Test individuals at risk for chronic HBV and/or HCV using the following CDC
guidelines:
-Patients who test positive for HCV antibody should also be tested for HCV RNA. This
distinguishes those who have an active HCV infection from those with past (inactive)
infections (Please note: HCV RIBA tests are no longer recommended).
-Patients who test positive for HBV surface antigen should have a repeat test with HBV
surface antigen, HBV DNA, and/or HBV envelope antigen no sooner than 6 months after
the first test. This distinguishes persons who are chronically infected with HBV from
persons who have resolved acute infection.
-All women should be screened for HBV surface antigen at the time of each pregnancy,
regardless of whether they have previously had a positive or negative test result. This
assists with timely provision of post-exposure prophylaxis to the infant at birth.
2. Offer Hepatitis A and B vaccination to all susceptible (HBV core antibody-negative)
HCV positive patients as well as susceptible household and sexual contacts of HBV
infected individuals.
3. Ask all patients about risk factors for chronic viral hepatitis, according to CDC’s
‘Populations at Risk’:
-Hepatitis B: http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#b4
-Hepatitis C: http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm#c1
4. Test all people born between 1945 and 1965 (ie, “baby boomers”) for HCV, regardless of
risk factors.
5. Educate all patients with current HBV or HCV infection about keeping their liver healthy
by avoiding alcohol and tobacco, and maintaining a healthy diet.
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Please continue reporting all positive viral hepatitis test results for Philadelphia residents to
PDPH within five days of receiving the results, by fax to 215-685-6947. For additional
information about this project, please call the Hepatitis Epidemiology Program at 215-685-6493.
To obtain resources and linkage to care information for patients with viral hepatitis in
Philadelphia, please contact The Viral Hepatitis Prevention Program at 215-685-6462.
Pennsylvania Code § 27 and Philadelphia Health Code § 6-202-mandate reporting of all positive
HBV and HCV test results for Philadelphia residents to PDPH. These Health Codes also give
PDPH the authority to investigate any reported case.

Announcement from the Philadelphia Department of Public Health to all health systems and
physicians in the Philadelphia that they would be commencing increased hepatitis monitoring
with the introduction of the CDC grant.
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Table 1
Action

Result

Impact

Realm of Influence: Risk Factors
-Downplays their stigma through
emphasis of “baby boomer” angle
in interviews
-Educate doctors about risk factors
and how they can facilitate
healthier conversation with their
patients about them
Realm of Influence: Systems of
Support
-Present at support group meetings
-Connect support groups to each
other
-Created information cards and
appointment cards for patients at
Prevention Point
-Translate letters and phone calls
for non-English speaking patients

Realm of Influence: Public
Health and Prevention
-Educate patients and community
leaders on the interconnectedness
of diagnosis and prevention
-Volunteer at Prevention Point
-Distribute materials to patients
and doctor’s offices
Realm of Influence: Stigmatized
Behaviors and Safe Practices
-Volunteer at Prevention Point
-Educate doctors on these risk
factors that are associated with
stigmatized behaviors
-Educate intravenous drug users on
safe practices
-Encourage condom use
-Monitor tattoo parlors and reports
of infection
Realm of Influence: Bodily Proof
and Silent Epidemics
-Educate on being asymptomatic
-Educate using analogies to mental

-Garners higher response rates on
surveys about risk factors
-Creates more detailed patients
records with their primary
physicians
-Creates a healthier repertoire
between doctor and patient

An elimination of stigma from the
conversations around diagnosis of
hepatitis empowering patients to be
tested without fear of judgement.

-Creates a network of HCV
awareness
-Help eliminate stigma
-Creates a space in which patients
and providers can feel more
comfortable with diagnosis and
treatment
-Demonstrating how support needs
to be tailored to an individual’s
needs

A space in which patients feel
comfortable and not discouraged
with their diagnosis because they
are aware of the resources available
to them.

-Demonstrating how social and
behavioral changes are a part of
health
-Takes isolated occurrences of
HCV and contextualizes them in a
way that makes HCV a community
concern-

A healthy dynamic between
individuals, their communities,
doctors and the Department of
Public Health that leads to
efficiency and lower rates of
infection.

-Transforms these behaviors and
choices from social problems to
issues of public health
-Create a safe space for discussion
of these behaviors without
judgment
-Create a safe community in which
behaviors do not have to result in
infection

Decreased stigma among the
community regarding drug use that
leads to healthier communities and
safe practices.

-Demonstrate that bodily proof is
not the only part of illness

Creates trust between the infected
and their community as to the
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health
-Educate on the frequency of HCV

Realm of Influence: Health
Insurance
-Educate patients in insurance
options
-Volunteer at Prevention Point

Realm of Influence: Medical
Hierarchy
-Work with doctors on data
collection
-Perform chart audits when doctors
do not comply

-Build awareness among those with
HCV that they shouldn’t await
diagnosis and treatment
-Allows patients to know they are
not the only ones with HCV

urgency of their needs.

-Raises awareness of flaws
-Creates an active participant in
one’s medical treatment
-Creates a space for protest against
the system
-Empowers patients

Creates an educated voting
populace who can demand change
in health policy.

-Enforces the authority of the
Department of Health with doctors
-Creates collaboration with doctors
encouraging teamwork on difficult
cases

Creates an environment in which
the expertise of everyone involved
in diagnosis, treatment, prevention
and monitoring is respected.

Table outlining the actions that the hepatitis team takes during implementation of the CDC grant
with observed results of the actions and surmised broader impacts of these actions.
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